Onconova Therapeutics, Inc. ( ONTX) Stock. Should you Buy or Sell? $ 1.17
0.01 (0.85 %)
Onconova Therapeutics, Inc. AnalysisUpdated on 10-09-2022
|Volume Avg.||$102.91 thousand|
|Market Cap||$24.45 M|
|52 Week Range||$1.0 - $6.77|
Onconova Therapeutics, Inc. opened the day at $1.17 which is +'0.85 % on yesterday's close. Onconova Therapeutics, Inc. has a 52 week high of $6.77 and 52 week low of $1.0, which is a difference of $5.77. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $24.45 M and total net profit is $226000 which means the company is trading at 108.18 times profit to market capitalization. Theoretically, if you were to buy Onconova Therapeutics, Inc. for $24.45 M, it would take 15 years to get your money back. Onconova Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Onconova Therapeutics, Inc. Stock Forecast - Is Onconova Therapeutics, Inc. a Buy or Sell?
|DCF Score||Strong Buy|
Growth and Value
|Net Profit Margin||-137.170|
Valuing Onconova Therapeutics, Inc.
|Price Book Value Ratio||0.636||Price To Book Ratio||0.636|
|Price To Sales Ratio||218.373||Price Earnings Ratio||-1.592|
How liquid is Onconova Therapeutics, Inc.
|Debt Ratio||0.199||Debt Equity Ratio||0.249|
|Long Term Debt To Capitalization||0.000||Total Debt To Capitalization||0.000|
Latest news about Onconova Therapeutics, Inc.
NEWTOWN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that the Company will be participating virtually in the H.C. Wainwright 24th Annual Global Investment Conference, which is taking place in a hybrid format at the Lotte New York Palace Hotel.
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors Steve Fruchtman - President & Chief Executive Officer Mark Gelder - Chief Medical Officer Mark Guerin - Chief Operating Officer & Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Chun Lung - Ladenburg Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by. Welcome to the Onconova Therapeutics Second Quarter 2022 Financial Results and Business Update Conference Call.
Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 5% and 5%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Onconova Therapeutics, Inc. (NASDAQ:ONTX ) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Avi Oler - Senior Vice President-Corporate Development and General Counsel Steve Fruchtman - President and Chief Executive Officer Mark Gelder - Chief Medical Officer Mark Guerin - Chief Financial Officer Conference Call Participants Charles Zhu - Guggenheim Ahu Demir - Ladenburg Joe Pantginis - H.C. Wainright Robert LeBoyer - Noble Capital Markets Operator Ladies and gentlemen, thank you for standing by.
NEWTOWN, Pa., March 23, 2022 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Adar Makovski Silverstein, Ph.D., Director of Corporate Development for Onconova, will present a high-level overview of the Company's narazaciclib program at the Next Generation Kinase Inhibitors Summit on March 30, 2022, at 2:00 p.m. ET.
About Onconova Therapeutics, Inc.
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.